Biogen to buy Apellis Pharmaceuticals
Signage outside the Biogen Inc. office in the Kendall Square neighborhood of Cambridge, Massachusetts, US, on Tuesday, Sept. 6, 2022. Adam Glanzman | Bloomberg | Getty Images Biogen has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, expanding its portfolio of rare-disease medicines, the companies said on Tuesday. The deal marks Biogen’s…